氨氯地平联合复方阿米洛利与联合替米沙坦治疗轻、中度高血压的疗效与安全性Meta分析

中国临床药理学与治疗学 ›› 2015, Vol. 20 ›› Issue (1): 70-74.

氨氯地平联合复方阿米洛利与联合替米沙坦治疗轻、中度高血压的疗效与安全性Meta分析

左珊如^1,2, 刘世坤², 左笑丛², 李兵², 吴翠芳², 李佐军², 王春江², 邓珍珍², 马玉桃^1,2

¹中南大学药学院,长沙 410013,湖南;
²中南大学湘雅三医院药剂科,长沙 410013,湖南

收稿日期:2013-11-30 修回日期:2014-03-12 发布日期:2020-07-20
通讯作者: 李兵,通信作者,男,副主任药师,研究方向:药事管理,临床药学。Tel:0731-88618187 E-mail:398111412@qq.com
作者简介:左珊如,女,硕士在读,研究方向:临床药学。E-mail:zuoshr@126.com

Meta-analysis of therapeutic efficacy and safety of amlodipine plus amiloride/hydrochlorothiazide and amlodipine plus telmisartan in the treatment of mild-to-moderate hypertension

ZUO Shan-ru^1,2, LIU Shi-kun², ZUO Xiao-cong², LI Bing², WU Cui-fang², LI Zuo-jun², WANG Chun-jiang², DENG Zhen-zhen², MA Yu-tao^1,2

¹School of Pharmaceltical Sciences of Central South University, Changsha 410013, Hunan, China;
²The Third Xiangya Hospital of Central South University, Changsha 410013, Hunan, China

Received:2013-11-30 Revised:2014-03-12 Published:2020-07-20

摘要/Abstract

摘要： 目的: 采用Meta分析系统评价氨氯地平联合复方阿米洛利与氨氯地平联合替米沙坦治疗轻、中度高血压的临床疗效及安全性的差异。方法: 以氨氯地平、复方阿米洛利、替米沙坦、高血压为主题词,检索 Pubmed、Web of Science、中国知网(CNKI)和万方数据库,收集氨氯地平联合复方阿米洛利或替米沙坦治疗高血压的相关文献,在严格的文献质量评价基础上,应用Meta分析对纳入的文献:研究氨氯地平分别联合复方阿米洛利、替米沙坦治疗轻、中度高血压的有效性与安全性,进行同质性检验及合并效应量的估计。结果: 共纳入13篇文献,16 192 例研究对象,其中复方阿米洛利组 8 098 例,替米沙坦组 8 094 例。有效性的同质检验:χ²=14.50, df=12,P=0.27;安全性的同质性检验:χ²=5.86,df=7,P=0.56。两者合并效应量的估计,有效性:OR合并=0.93,95%可信区间为 0.81～1.06。安全性OR合并=1.23,95%可信区间为 1.04～1.45。结论: 氨氯地平联合复方阿米洛利治疗轻、中度高血压有效性与氨氯地平联合替米沙坦无统计学差异,但安全性方面氨氯地平联合替米沙坦优于氨氯地平联合复方阿米洛利。

关键词: 复方阿米洛利, 氨氯地平, 替米沙坦, 轻、中度高血压, Meta分析

Abstract: AIM: To evaluate the clinical efficacy and safety of amlodipine plus amiloride/hydrochlorothiazide and amlodipine plus telmisartan in the treatment of mild-to-moderate hypertension by Meta-analysis. METHODS: Pubmed, Web of Science, CNKI and Wanfang Database were searched for combination of amlodipine plus amiloride/hydrochlorothiazide and amlodipine plus telmisartan on hypertension treatment using the key words “amlodipine”, “amiloride/hydrochlorothiazide”, “telmisartan” and “hypertension”, supplemented literature recourse method to retrieve. The effectiveness and safety of amlodipine plus amiloride/hydrochlorothiazide and amlodipine plus telmisartan agents and overall effect tests based on strict quality evaluation of clinical trials. RESULTS: 13 literatures and 16 192 patients were included in this study, which consisted of 8 098 cases in amiloride/hydrochlorothiazide group and 8 094 cases in telmisartan group. The result of homogeneity test of efficacy was:χ²=14.50, df=12,P=0.27;while that of safety was χ²=5.86,df=7,P=0.56. The combined ORs and 95％CIs were 0.93,0.81-1.06 for efficacy and 1.23,1.04-1.45 for safety,respectively. CONCLUSION: There is no significant difference in therapeutic efficacy between amlodipine plus amiloride /hydrochlorothiazide and amlodipine plus telmisartan in the treatment of mild-to-moderate hypertension, but amlodipine plus telmisartan is safer and has less adverse reaction.

Key words: amiloride/hydrochlorothiazide, amlodipine, telmisartan, mild-to-moderate hypertension, Meta-analysis

中图分类号:

R969.1

左珊如, 刘世坤, 左笑丛, 李兵, 吴翠芳, 李佐军, 王春江, 邓珍珍, 马玉桃. 氨氯地平联合复方阿米洛利与联合替米沙坦治疗轻、中度高血压的疗效与安全性Meta分析[J]. 中国临床药理学与治疗学, 2015, 20(1): 70-74.

ZUO Shan-ru, LIU Shi-kun, ZUO Xiao-cong, LI Bing, WU Cui-fang, LI Zuo-jun, WANG Chun-jiang, DENG Zhen-zhen, MA Yu-tao. Meta-analysis of therapeutic efficacy and safety of amlodipine plus amiloride/hydrochlorothiazide and amlodipine plus telmisartan in the treatment of mild-to-moderate hypertension[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 70-74.

参考文献

[1] 刘红艳,彭辉,刘奥博,等.中国人原发性高血压危险因素Meta分析[J].中国心血管杂志,2009,14(3):205-209.
[2] 李颖,崔嵘,袁洪,等.小剂量氨氯地平联合用药治疗老年高血压的疗效和安全性评价[J].中国老年学杂志,2010,30(8):1021-1024.
[3] 董凯霞. 小剂量氨氯地平联合复方阿米洛利治疗老年高血压的疗效及安全性[J].中国老年学杂志,2012,32(17):3671-3672.
[4] 桑海强,宁建平,孙明,等.初始联治疗策略对高血压患者的疗效及肾功能的影响[J].医学临床研究,2010,27(4):610-613.
[5] 周展.参加国家十一五课题《中国高血压综合防治研究》的体会[D].福建:福建医科大学,2009.
[6] 贾颖,袁洪,黄志军,等. 氨氯地平为基础的不同用药方案治疗原发性高血压的疗效观察[J].现代医药卫生,2010,26(19):2883-2885.
[7] 何小娟,何晓骥. 氨氯地平联合替米沙坦与氨氯地平联合阿米洛利治疗原发性高血压对比分析[J].中国医药指南,2011,9(22):78-79.
[8] 舒瑛,张艳梅,陈复琼,等. 氨氯地平联合替米沙坦或复方阿米洛利的疗效及安全性比较[J].药物流行病学杂志,2011,20(6):275-278.
[9] 牛惠英. 氨氯地平联合复方阿米洛利或替米沙坦治疗原发性高血压疗效比较[J].中西医结合心脑血管病杂,2011,9(6):672-674.
[10] 俞蔚, 唐新华, 王文,等.氨氯地平联合复方阿米洛利或替米沙坦对高血压患者降压疗效的相关临床因素分析[J].中国临床药理学与治疗,2010,15(11):1273-1278.
[11] 孙尚文,路方红,孙颖,等. 氨氯地平联合复方阿米洛利或联合替米沙坦对高血压患者颈动脉粥样硬化的对比研究[J].中华高血压杂志,2011,19(8):763-767.
[12] 沈江山.氨氯地平分别与替米沙坦及复方阿米洛利联合应用治疗轻中度高血压的临床研究[D].南昌:南昌大学,2010.
[13] Ma L, Wang W, Zhao Y, et al. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study [J]. Am J Cardiovasc Drugs, 2012,12 (2):137-142.
[14] Lu F, Zhao Y, Liu Z, et al. A 48-week study of amlodipine plus amiloride? hydrochlorothiazide vs. amlodipine plus telmisartan in the treatment of hypertension[J]. Int J Clin Pract, 2012, 66(8):792-799.
[15] 汪全海,贺连平,陈燕,等.氨氯地平联合替米沙坦改善高血压合并糖尿病患者微蛋白尿效果的Meta分析[J].中国临床药理学与治疗学,2013,18(7):774-777.